NCT07469956 2026-03-13Surufatinib Plus mFOLFIRINOX and PD-1 Inhibitor as the Neoadjuvant Therapy for High-risk or Borderline Resectable Pancreatic CancerSun Yat-sen UniversityPhase 2 Not yet recruiting30 enrolled
NCT06361888 2025-12-30A Phase II/III Trial to Evaluate the Efficacy and Safety of Surufatinib Combined With Camrelizumab, Nab-paclitaxel, and Gemcitabine in Metastatic Pancreatic CancerHutchmedPhase 2/3 Recruiting502 enrolled